Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dovramilast

Phase 2Small molecule

MMedicines Development for Global Health

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erythema Nodosum LeprosumRecruiting

Erythema Nodosum LeprosumPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Erythema Nodosum Leprosum

NCT07172659

Clinical

Trials by Indication[1]

Erythema Nodosum Leprosum1 trial

A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction

Recruiting·MMedicines Development for Global Health·Phase 2·NCT07172659·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dovramilast. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dovramilast compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dovramilast. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medicines Development for Global Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedicines Development for Global Health

Related News